These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15517817)

  • 1. [Laboratory assessment problems of the efficacy of acellular pertussis vaccines].
    Gzyl A
    Przegl Epidemiol; 2004; 58(2):361-7. PubMed ID: 15517817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines.
    Gaines-Das R; Horiuchi Y; Zhang SM; Newland P; Kim Y; Corbel M; Xing D
    Vaccine; 2009 Nov; 27(49):6824-32. PubMed ID: 19765397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands.
    David S; Vermeer-de Bondt PE; van der Maas NA
    Vaccine; 2008 Oct; 26(46):5883-7. PubMed ID: 18775463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines.
    Xing D; Maes A; Behr-Gross ME; Costanzo A; Daas A; Buchheit KH
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):51-63. PubMed ID: 20223190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WHO working group on standardisation and control of acellular pertussis vaccines--report of a meeting held on 16-17 March 2006, St. Albans, United Kingdom.
    Xing DK; Corbel MJ; Dobbelaer R; Knezevic I
    Vaccine; 2007 Apr; 25(15):2749-57. PubMed ID: 17368348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key points for the development of mouse immunogenicity test as potency assay for acellular pertussis vaccines.
    André M; Poirier B; Bornstein N; Marmonier D; El Zaouk A; Fuchs F
    Biologicals; 2000 Dec; 28(4):217-25. PubMed ID: 11237357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardization of acellular pertussis vaccines.
    Kreeftenberg JG
    Biologicals; 1999 Jun; 27(2):115-7. PubMed ID: 10600198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination.
    Rieber N; Graf A; Belohradsky BH; Hartl D; Urschel S; Riffelmann M; Wirsing von König CH; Liese J
    Vaccine; 2008 Dec; 26(52):6929-35. PubMed ID: 18852002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of recent clinical trials of acellular pertussis vaccines.
    Miller E
    Biologicals; 1999 Jun; 27(2):79-86. PubMed ID: 10600188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acellular pertussis vaccines in China.
    Wang L; Lei D; Zhang S
    Vaccine; 2012 Nov; 30(50):7174-8. PubMed ID: 23084855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].
    van der Maas NA; David S; Kemmeren JM; Vermeer-de Bondt PE
    Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2732-7. PubMed ID: 18225797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.
    Hallander HO; Ljungman M; Storsaeter J; Gustafsson L
    APMIS; 2009 Nov; 117(11):797-807. PubMed ID: 19845530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular immunity in adolescents and adults following acellular pertussis vaccine administration.
    Meyer CU; Zepp F; Decker M; Lee M; Chang SJ; Ward J; Yoder S; Bogaert H; Edwards KM
    Clin Vaccine Immunol; 2007 Mar; 14(3):288-92. PubMed ID: 17267589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of pertussis whole cell and acellular vaccines on pulmonary immunology in an aerosol challenge model.
    Carter CR; Dagg BM; Whitmore KM; Keeble JR; Asokanathan C; Xing D; Walker KB
    Cell Immunol; 2004 Jan; 227(1):51-8. PubMed ID: 15051514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of pertussis and high expectations concerning vaccines].
    Wysocki J
    Przegl Epidemiol; 2004; 58 Suppl 1():39-43. PubMed ID: 15807156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines.
    Geier DA; Geier MR
    Brain Dev; 2004 Aug; 26(5):296-300. PubMed ID: 15165669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine and antibody profiles in 1-year-old children vaccinated with either acellular or whole-cell pertussis vaccine during infancy.
    Dirix V; Verscheure V; Goetghebuer T; Hainaut M; Debrie AS; Locht C; Mascart F
    Vaccine; 2009 Oct; 27(43):6042-7. PubMed ID: 19665604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An alternative temperature-based histamine-sensitisation test for absence of residual pertussis toxin in acellular pertussis vaccines.
    Jensen SE; Engelhart Illigen KE; Hasløv KR
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):73-4. PubMed ID: 20223192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acellular pertussis vaccines in Japan: past, present and future.
    Watanabe M; Nagai M
    Expert Rev Vaccines; 2005 Apr; 4(2):173-84. PubMed ID: 15889991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children.
    Lacombe K; Yam A; Simondon K; Pinchinat S; Simondon F
    Vaccine; 2004 Dec; 23(5):623-8. PubMed ID: 15542182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.